Kevin O O O O
Kavanagh, O O O O
MD, O O O O
discusses O O O O
the O O O O
continued O O O O
concerns O O O O
about O O O O
COVID-19 O O O O
vaccine O O O O
efficacy O O O O
reduction O O O O
and O O O O
what O O O O
he O O O O
believes O O O O
should O O O O
be O O O O
done O O O O
to O O O O
protect O O O O
against O O O O
the O O O O
further O O O O
spread. O O O O
The O O O O
United O O O O
States O O O O
Vaccine O O O O
effort O O O O
is O O O O
starting O O O O
to O O O O
falter O O O O
in O O O O
terms O O O O
of O O O O
efficacy O O O O
and O O O O
public O O O O
acceptance. O O O O
On O O O O
November O O O O
1, O O O O
2022, O O O O
Infection O O O O
Control O O O O
Today® O O O O
(ICT®) O O O O
published O O O O
an O O O O
[article O O O O
questioning O O O O
our O O O O
current O O O O
booster O O O O
formulation](https://protect-us.mimecast.com/s/_ieYCxkmBmSxM2NQivaloY?domain=infectioncontroltoday.com). O O O O
On O O O O
[December O O O O
9, O O O O
2022, O O O O
a O O O O
commentary O O O O
published O O O O
in O O O O
The O O O O
Journal O O O O
of O O O O
the O O O O
American O O O O
Medical O O O O
Association O O O O
(JAMA) O O O O
Network](https://protect-us.mimecast.com/s/RXsdCyPnDnCLXlVysQg8e4?domain=jamanetwork.com) O O O O
entitled O O O O
"Urgent O O O O
Need O O O O
for O O O O
Next-Generation O O O O
COVID-19 O O O O
Vaccines" O O O O
also O O O O
sounded O O O O
the O O O O
alarm. O O O O
The O O O O
efficacy O O O O
of O O O O
boosters O O O O
in O O O O
preventing O O O O
severe O O O O
disease O O O O
in O O O O
the O O O O
elderly O O O O
was O O O O
still O O O O
high O O O O
during O O O O
a O O O O
period O O O O
that O O O O
BA.4/5 O O O O
predominated. O O O O
A O O O O
recent O O O O
study O O O O
published O O O O
in O O O O
the O O O O
Centers O O O O
for O O O O
Disease O O O O
Control O O O O
and O O O O
Prevention's O O O O
(CDC's) O O O O
Morbidity O O O O
and O O O O
Mortality O O O O
Weekly O O O O
Report O O O O
(MMWR) O O O O
explains O O O O
that O O O O
the O O O O
new O O O O
bivalent O O O O
BA.5 O O O O
booster O O O O
has O O O O
a O O O O
[73% O O O O
efficacy O O O O
in O O O O
preventing O O O O
hospitalizations](https://protect-us.mimecast.com/s/dXj0CzpoEoU4g0VmcKNI7m?domain=cdc.gov) O O O O
in O O O O
those O O O O
aged O O O O
65 O O O O
years O O O O
and O O O O
older O O O O
who O O O O
have O O O O
received O O O O
a O O O O
prior O O O O
vaccination O O O O
or O O O O
monovalent O O O O
booster O O O O
(84% O O O O
efficacy O O O O
compared O O O O
to O O O O
unvaccinated). O O O O
Those O O O O
[18 O O O O
and O O O O
older O O O O
had O O O O
just O O O O
a O O O O
38% O O O O
efficacy](https://protect-us.mimecast.com/s/FJCyCADx2xfE6vq1SQEtJY?domain=msn.com) O O O O
in O O O O
preventing O O O O
hospitalizations O O O O
compared O O O O
to O O O O
individuals O O O O
who O O O O
had O O O O
prior O O O O
vaccinations O O O O
or O O O O
monovalent O O O O
booster. O O O O
However, O O O O
there O O O O
was O O O O
only O O O O
a O O O O
2- O O O O
to O O O O
5-month O O O O
follow-up, O O O O
which O O O O
is O O O O
extremely O O O O
short, O O O O
and O O O O
further O O O O
waning O O O O
may O O O O
occur. O O O O
In O O O O
addition, O O O O
these O O O O
vaccines O O O O
and O O O O
boosters O O O O
no O O O O
longer O O O O
effectively O O O O
prevent O O O O
the O O O O
spread O O O O
of O O O O
SARS-CoV-2, O O O O
and O O O O
the O O O O
prevention O O O O
of O O O O
spread O O O O
is O O O O
key O O O O
to O O O O
preventing O O O O
long O O O O
COVID-19 O O O O
and O O O O
future O O O O
viral O O O O
mutations. O O O O
This O O O O
efficacy O O O O
reduction O O O O
is O O O O
happening O O O O
simultaneously O O O O
as O O O O
infections O O O O
from O O O O
variants O O O O
with O O O O
even O O O O
more O O O O
significant O O O O
immune O O O O
escape O O O O
potential O O O O
are O O O O
increasing O O O O
in O O O O
our O O O O
nation. O O O O
The O O O O
BQ.1, O O O O
BQ1.1, O O O O
XBB, O O O O
and O O O O
XBB.1 O O O O
subvariants O O O O
are O O O O
resistant O O O O
to O O O O
[recent O O O O
study O O O O
published O O O O
in O O O O
Cell](https://protect-us.mimecast.com/s/-tGLC73kwkuZqZ2oi8GVgt?domain=cell.com), O O O O
stated O O O O
"All O O O O
clinical O O O O
monoclonal O O O O
antibodies O O O O
were O O O O
rendered O O O O
inactive O O O O
against O O O O
these O O O O
variants." O O O O
The O O O O
article O O O O
also O O O O
stated O O O O
that O O O O
these O O O O
variants O O O O
pose O O O O
a O O O O
significant O O O O
threat O O O O
to O O O O
the O O O O
efficacy O O O O
of O O O O
the O O O O
bivalent O O O O
booster. O O O O
Even O O O O
more O O O O
concerning O O O O
is O O O O
that O O O O
there O O O O
may O O O O
be O O O O
[significant O O O O
immune O O O O
imprinting O O O O
with O O O O
the O O O O
mRNA O O O O
vaccines](https://protect-us.mimecast.com/s/JRfICDkA2AS3vRGOHRRuie?domain=infectioncontroltoday.com). O O O O
[Immune O O O O
imprinting O O O O
was O O O O
evident](https://protect-us.mimecast.com/s/JRfICDkA2AS3vRGOHRRuie?domain=infectioncontroltoday.com) O O O O
in O O O O
the O O O O
animal O O O O
data O O O O
presented O O O O
to O O O O
the O O O O
CDC's O O O O
vaccine O O O O
committee. O O O O
All O O O O
animals O O O O
were O O O O
given O O O O
the O O O O
monovalent O O O O
vaccine O O O O
to O O O O
the O O O O
original O O O O
wild-type O O O O
virus. O O O O
The O O O O
mice O O O O
were O O O O
then O O O O
given O O O O
either O O O O
a O O O O
monovalent O O O O
booster O O O O
containing O O O O
the O O O O
original O O O O
spike O O O O
protein, O O O O
the O O O O
BA.1 O O O O
spike O O O O
protein, O O O O
the O O O O
BA.5 O O O O
spike O O O O
protein, O O O O
or O O O O
a O O O O
bivalent O O O O
booster O O O O
that O O O O
contained O O O O
both O O O O
the O O O O
wild-type O O O O
(original) O O O O
and O O O O
BA.5 O O O O
spike O O O O
protein. O O O O
Surprisingly, O O O O
the O O O O
immune O O O O
response O O O O
to O O O O
the O O O O
original O O O O
wild-type O O O O
virus O O O O
from O O O O
the O O O O
BA.5 O O O O
monovalent O O O O
booster O O O O
was O O O O
essentially O O O O
the O O O O
same O O O O
as O O O O
that O O O O
elicited O O O O
by O O O O
the O O O O
original O O O O
monovalent O O O O
booster. O O O O
And O O O O
the O O O O
elicited O O O O
BA.5 O O O O
booster O O O O
response O O O O
to O O O O
the O O O O
wild-type O O O O
virus O O O O
was O O O O
larger O O O O
than O O O O
that O O O O
to O O O O
the O O O O
BA.5 O O O O
variant. O O O O
Thus, O O O O
immune O O O O
imprinting O O O O
may O O O O
be O O O O
taking O O O O
place O O O O
where O O O O
the O O O O
maximal O O O O
boost O O O O
in O O O O
response O O O O
is O O O O
to O O O O
the O O O O
original O O O O
virus O O O O
one O O O O
is O O O O
exposed O O O O
to. O O O O
This O O O O
concern O O O O
is O O O O
supported O O O O
by O O O O
the O O O O
[research O O O O
of O O O O
Roltgen O O O O
K O O O O
et O O O O
al](https://protect-us.mimecast.com/s/Unz5CERB2BHp9QX6Sxwlun?domain=sciencedirect.com), O O O O
which O O O O
found O O O O
that O O O O
"Viral O O O O
variant O O O O
infection O O O O
elicits O O O O
variant-specific O O O O
antibodies, O O O O
but O O O O
prior O O O O
mRNA O O O O
vaccination O O O O
imprints O O O O
serological O O O O
responses O O O O
toward O O O O
Wuhan-Hu-1 O O O O
rather O O O O
than O O O O
variant O O O O
antigens." O O O O
Prior O O O O
infections O O O O
have O O O O
also O O O O
been O O O O
observed O O O O
to O O O O
cause O O O O
imprinting. O O O O
[Reynolds O O O O
et O O O O
al,](https://protect-us.mimecast.com/s/Ap_VC5ygrgT6jlwOIzLCsN?domain=science.org) O O O O
found O O O O
that O O O O
"Omicron O O O O
infection O O O O
after O O O O
previous O O O O
Wuhan O O O O
Hu-1 O O O O
infection O O O O
failed O O O O
to O O O O
boost O O O O
neutralizing O O O O
antibody O O O O
and O O O O
T O O O O
cell O O O O
responses O O O O
against O O O O
Omicron, O O O O
revealing O O O O
a O O O O
profound O O O O
imprinting O O O O
effect O O O O
and O O O O
explaining O O O O
why O O O O
frequent O O O O
reinfections O O O O
occur." O O O O
This O O O O
finding O O O O
received O O O O
far O O O O
too O O O O
little O O O O
attention O O O O
and O O O O
foretold O O O O
the O O O O
findings O O O O
in O O O O
[research O O O O
papers O O O O
reporting O O O O
only O O O O
marginal O O O O
if O O O O
any, O O O O
increased O O O O
benefit](https://protect-us.mimecast.com/s/_ieYCxkmBmSxM2NQivaloY?domain=infectioncontroltoday.com) O O O O
of O O O O
the O O O O
bivalent O O O O
booster O O O O
over O O O O
the O O O O
original O O O O
booster. O O O O
Questions Reason 2 O O
Linger Reason 2 O O
For Reason 2 O O
children, Reason 2 O O
we Reason 2 O O
must Reason 2 O O
ask, Reason 2 O O
do Reason 2 O O
we Reason 2 O O
want Reason 2 O O
to Reason 2 O O
continue Reason 2 O O
to Reason 2 O O
imprint Reason 2 O O
them Reason 2 O O
with Reason 2 O O
the Reason 2 O O
original Reason 2 O O
variant? Reason 2 O O
Or Reason 2 O O
would Reason 2 O O
it Reason 2 O O
be Reason 2 O O
better Reason 2 O O
to Reason 2 O O
use Reason 2 O O
a Reason 2 O O
bivalent Reason 2 O O
or Reason 2 O O
monovalent Reason 2 O O
version Reason 2 O O
of Reason 2 O O
the Reason 2 O O
vaccine Reason 2 O O
targeting Reason 2 O O
a Reason 2 O O
recent Reason 2 O O
variant? Reason 2 O O
Should Reason 2 O O
Pfizer Reason 2 O O
& Reason 2 O O
Moderna Reason 2 O O
discard Reason 2 O O
much Reason 2 O O
of Reason 2 O O
their Reason 2 O O
old Reason 2 O O
stock Reason 2 O O
and Reason 2 O O
reformulate Reason 2 O O
their Reason 2 O O
vaccine? Reason 2 O O
For Reason 2 O O
mRNA, Reason 2 O O
pharmaceutical Reason 2 O O
[companies Reason 2 O O
appear Reason 2 O O
to Reason 2 O O
be Reason 2 O O
making Reason 2 O O
billions](https://protect-us.mimecast.com/s/OOXxCG6E2EiAYVXLtrlo0E?domain=cnn.com) Reason 2 O O
from Reason 2 O O
vaccine Reason 2 O O
sales. Reason 2 O O
Should Reason 2 O O
they Reason 2 O O
immediately Reason 2 O O
reformulate Reason 2 O O
whenever Reason 2 O O
a Reason 2 O O
new Reason 2 O O
dominant Reason 2 O O
variant Reason 2 O O
arises? Reason 2 O O
This Reason 2 O O
may Reason 2 O O
well Reason 2 O O
be Reason 2 O O
a Reason 2 O O
3- Reason 2 O O
to Reason 2 O O
4-month Reason 2 O O
cycle. Reason 2 O O
This, Reason 2 O O
of Reason 2 O O
course, Reason 2 O O
would Reason 2 O O
be Reason 2 O O
a Reason 2 O O
stopgap Reason 2 O O
measure. Reason 2 O O
Reformulation Reason 2 O O
of Reason 2 O O
variant-specific Reason 2 O O
vaccines Reason 2 O O
when Reason 2 O O
variants Reason 2 O O
are Reason 2 O O
arising Reason 2 O O
at Reason 2 O O
such Reason 2 O O
a Reason 2 O O
rapid Reason 2 O O
rate Reason 2 O O
is Reason 2 O O
not Reason 2 O O
a Reason 2 O O
long-term Reason 2 O O
strategy. Reason 2 O O
Prevention Reason 2 O O
of Reason 2 O O
spread Reason 2 O O
is Reason 2 O O
of Reason 2 O O
utmost Reason 2 O O
importance. Reason 2 O O
With Reason 2 O O
the Reason 2 O O
dangers Reason 2 O O
of Reason 2 O O
long Reason 2 O O
COVID-19 Reason 2 O O
and Reason 2 O O
the Reason 2 O O
mounting Reason 2 O O
deaths Reason 2 O O
( Reason 2 O O
[potentially Reason 2 O O
almost Reason 2 O O
doubling](https://protect-us.mimecast.com/s/FPAtCJ6R2RiKr7MQHKzpQb?domain=nature.com) Reason 2 O O
the Reason 2 O O
total Reason 2 O O
from Reason 2 O O
acute Reason 2 O O
COVID-19) Reason 2 O O
and Reason 2 O O
disability Reason 2 O O
from Reason 2 O O
this Reason 2 O O
disease, Reason 2 O O
we Reason 2 O O
must Reason 2 O O
set Reason 2 O O
our Reason 2 O O
goal Reason 2 O O
at Reason 2 O O
the Reason 2 O O
prevention Reason 2 O O
of Reason 2 O O
spread. Reason 2 O O
This Reason 2 O O
pandemic Reason 2 O O
is Reason 2 O O
damaging Reason 2 O O
the Reason 2 O O
cardiovascular Reason 2 O O
and Reason 2 O O
central Reason 2 O O
nervous Reason 2 O O
systems Reason 2 O O
of Reason 2 O O
far Reason 2 O O
too Reason 2 O O
many Reason 2 O O
individuals. Reason 2 O O
The Reason 2 O O
latter Reason 2 O O
is Reason 2 O O
causing Reason 2 O O
brain Reason 2 O O
fog, Reason 2 O O
memory, Reason 2 O O
and Reason 2 O O
what Reason 2 O O
I Reason 2 O O
like Reason 2 O O
to Reason 2 O O
call Reason 2 O O
[COVID-19 Reason 2 O O
Personality Reason 2 O O
Disorder](https://protect-us.mimecast.com/s/PfodCKrR2Ri4EjprckijwM?domain=infectioncontroltoday.com). Reason 2 O O
Yes, Reason 2 O O
infections Reason 2 O O
through Reason 2 O O
environmental Reason 2 O O
stresses Reason 2 O O
and Reason 2 O O
physical Reason 2 O O
brain Reason 2 O O
damage Reason 2 O O
can Reason 2 O O
change Reason 2 O O
one's Reason 2 O O
personality. Reason 2 O O
Immune Reason 2 O O
dysfunction Reason 2 O O
from Reason 2 O O
COVID-19 Reason 2 O O
is Reason 2 O O
another Reason 2 O O
concern, Reason 2 O O
as Reason 2 O O
evidenced Reason 2 O O
by Reason 2 O O
the Reason 2 O O
overwhelming Reason 2 O O
number Reason 2 O O
of Reason 2 O O
RSV Reason 2 O O
hospitalizations. Reason 2 O O
This Reason 2 O O
occurred Reason 2 O O
even Reason 2 O O
though, Reason 2 O O
at Reason 2 O O
the Reason 2 O O
beginning Reason 2 O O
of Reason 2 O O
December, Reason 2 O O
we Reason 2 O O
had Reason 2 O O
more Reason 2 O O
RSV Reason 2 O O
cases Reason 2 O O
in Reason 2 O O
2021 Reason 2 O O
than Reason 2 O O
we Reason 2 O O
had Reason 2 O O
in Reason 2 O O
2022. Reason 2 O O
The Reason 2 O O
best Reason 2 O O
hope Reason 2 O O
of Reason 2 O O
blocking Reason 2 O O
transmission Reason 2 O O
is Reason 2 O O
with Reason 2 O O
mucosal Reason 2 O O
vaccines. Reason 2 O O
The Reason 2 O O
current Reason 2 O O
mRNA Reason 2 O O
vaccines Reason 2 O O
[do Reason 2 O O
not Reason 2 O O
produce Reason 2 O O
a Reason 2 O O
robust Reason 2 O O
IgA Reason 2 O O
mucosal Reason 2 O O
response](https://protect-us.mimecast.com/s/_-_BCL9R2RhQjJ8YSYDWIo?domain=nature.com) Reason 2 O O
and, Reason 2 O O
thus, Reason 2 O O
have Reason 2 O O
low Reason 2 O O
efficacy Reason 2 O O
in Reason 2 O O
preventing Reason 2 O O
infections Reason 2 O O
and Reason 2 O O
spread. Reason 2 O O
We Reason 2 O O
need Reason 2 O O
a Reason 2 O O
warp Reason 2 O O
speed Reason 2 O O
on Reason 2 O O
new Reason 2 O O
vaccine Reason 2 O O
development. Reason 2 O O
Why Reason 2 O O
this Reason 2 O O
is Reason 2 O O
not Reason 2 O O
being Reason 2 O O
done Reason 2 O O
is Reason 2 O O
one Reason 2 O O
of Reason 2 O O
the Reason 2 O O
most Reason 2 O O
significant Reason 2 O O
failings Reason 2 O O
of Reason 2 O O
our Reason 2 O O
pandemic Reason 2 O O
response. Reason 2 O O
Until Reason 2 O O
we Reason 2 O O
have Reason 2 O O
a Reason 2 O O
vaccine Reason 2 O O
that Reason 2 O O
stops Reason 2 O O
spread, Reason 2 O O
we Reason 2 O O
need Reason 2 O O
to Reason 2 O O
use Reason 2 O O
N95 Reason 2 O O
masks, Reason 2 O O
avoid Reason 2 O O
crowded Reason 2 O O
indoor Reason 2 O O
venues, Reason 2 O O
and Reason 2 O O
markedly Reason 2 O O
increase Reason 2 O O
indoor Reason 2 O O
ventilation Reason 2 O O
and Reason 2 O O
air Reason 2 O O
sanitization Reason 2 O O
(with Reason 2 O O
upper Reason 2 O O
room Reason 2 O O
UV-C Reason 2 O O
units). Reason 2 O O
Immediate Reason 2 O O
action Reason 2 O O
is Reason 2 O O
needed; Reason 2 O O
one Reason 2 O O
should Reason 2 O O
strongly Reason 2 O O
consider Reason 2 O O
the Reason 2 O O
following: Reason 2 O O
1. Reason 2 O O
Administering Reason 2 O O
a Reason 2 O O
bivalent Reason 2 O O
or Reason 2 O O
monovalent Reason 2 O O
BA.5 Reason 2 O O
(or Reason 2 O O
current Reason 2 O O
variant) Reason 2 O O
vaccine Reason 2 O O
to Reason 2 O O
COVID-19-naive Reason 2 O O
individuals, Reason 2 O O
especially Reason 2 O O
young Reason 2 O O
children. Reason 2 O O
2. Reason 2 O O
Administering Reason 2 O O
a Reason 2 O O
monovalent Reason 2 O O
BA.5 Reason 2 O O
(or Reason 2 O O
latest Reason 2 O O
variant) Reason 2 O O
booster Reason 2 O O
to Reason 2 O O
those Reason 2 O O
previously Reason 2 O O
vaccinated Reason 2 O O
or Reason 2 O O
infected Reason 2 O O
with Reason 2 O O
COVID-19. Reason 2 O O
3. Reason 2 O O
Vaccine Reason 2 O O
reformulation Reason 2 O O
upon Reason 2 O O
each Reason 2 O O
emergent Reason 2 O O
wave Reason 2 O O
of Reason 2 O O
the Reason 2 O O
virus Reason 2 O O
is Reason 2 O O
a Reason 2 O O
stopgap Reason 2 O O
measure, Reason 2 O O
but Reason 2 O O
it Reason 2 O O
must Reason 2 O O
be Reason 2 O O
implemented Reason 2 O O
to Reason 2 O O
the Reason 2 O O
best Reason 2 O O
extent Reason 2 O O
possible. Reason 2 O O
4. Reason 2 O O
Funding Reason 2 O O
a Reason 2 O O
new Reason 2 O O
Warp Reason 2 O O
Speed Reason 2 O O
initiative Reason 2 O O
designed Reason 2 O O
to Reason 2 O O
develop Reason 2 O O
mucosal Reason 2 O O
vaccines. Reason 2 O O
5. Reason 2 O O
And, Reason 2 O O
of Reason 2 O O
course, Reason 2 O O
the Reason 2 O O
use Reason 2 O O
of Reason 2 O O
N95 Reason 2 O O
masks Reason 2 O O
and Reason 2 O O
increasing Reason 2 O O
indoor Reason 2 O O
ventilation, Reason 2 O O
along Reason 2 O O
with Reason 2 O O
the Reason 2 O O
help Reason 2 O O
of Reason 2 O O
upper Reason 2 O O
room Reason 2 O O
UV-C, Reason 2 O O
is Reason 2 O O
of Reason 2 O O
utmost Reason 2 O O
importance. Reason 2 O O
But Reason 2 O O
above Reason 2 O O
all, Reason 2 O O
we Reason 2 O O
need Reason 2 O O
to Reason 2 O O
incorporate Reason 2 O O
the Reason 2 O O
new Reason 2 O O
data Reason 2 O O
we Reason 2 O O
have Reason 2 O O
gathered Reason 2 O O
and Reason 2 O O
lessons Reason 2 O O
we Reason 2 O O
have Reason 2 O O
learned Reason 2 O O
to Reason 2 O O
create Reason 2 O O
a Reason 2 O O
more Reason 2 O O
effective Reason 2 O O
strategy Reason 2 O O
in Reason 2 O O
our Reason 2 O O
approach Reason 2 O O
to Reason 2 O O
COVID-19. Reason 2 O O
